Aptevo stock spikes as new AML trial data show 85% remission rate with mipletamig triplet therapy, supported by strong safety and no CRS observed.
Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer
Where Today's News Shapes Tomorrow
